Company Overview

Evogene Ltd. is an Israeli computational biology company focused on developing product-based solutions for agriculture and life sciences through advanced predictive biology. The company operates at the intersection of agricultural biotechnology, computational biology, and artificial intelligence, using proprietary algorithms to improve the discovery and development of biological products. Evogene’s technology platform is designed to identify and optimize genes, microbes, and small molecules for commercial applications.

The company’s primary revenue drivers historically include research collaborations, licensing agreements, and milestone-based payments, alongside emerging product commercialization through subsidiaries. Evogene serves agricultural input companies, seed developers, and crop protection markets, with a strategic emphasis on sustainable agriculture. Founded in 2002 as a spin-off from Compugen, Evogene has evolved from a pure discovery partner into a holding company operating multiple specialized subsidiaries, each focused on a defined biological domain.

Business Operations

Evogene operates through several distinct business units built around its proprietary Predictive Biology Platform, which integrates big data, machine learning, and biological modeling. Its core operating subsidiaries include Lavie Bio Ltd. (microbiome-based agricultural biologicals), Biomica Ltd. (microbiome-based therapeutics, historically focused on human health), AgPlenus Ltd. (novel crop protection products), and Canonic Ltd. (medical cannabis genetics and traits). Each subsidiary operates with its own management team while leveraging Evogene’s centralized computational infrastructure.

The company generates revenue through a combination of strategic partnerships, licensing agreements, and development services, as well as equity investments in its subsidiaries. Operations are primarily research- and development-driven, with commercialization efforts often conducted in collaboration with multinational agricultural and life science companies. Evogene maintains intellectual property ownership over its core computational technologies, which underpin product discovery across its portfolio.

Strategic Position & Investments

Evogene’s strategy centers on advancing its subsidiaries toward value-creating inflection points, including commercial launches, strategic partnerships, or external investments. Growth initiatives emphasize sustainable agriculture, biological alternatives to chemical inputs, and data-driven trait discovery. The company has historically invested capital and intellectual property into its subsidiaries rather than pursuing large-scale external acquisitions.

Notable investments include continued funding and ownership stakes in Lavie Bio Ltd., AgPlenus Ltd., and Canonic Ltd., which are positioned in emerging sectors such as agricultural biologicals and plant-derived compounds. Evogene’s technology platform remains a strategic asset, enabling entry into new biological domains while maintaining optionality for future spin-outs or collaborations. Where subsidiary performance or market traction varies, public disclosures note differing stages of maturity and capital requirements.

Geographic Footprint

Evogene is headquartered in Israel, where it conducts the majority of its research and development activities. The company’s operations are primarily based in the Middle East, with Israel serving as its innovation and management hub. Its subsidiaries also maintain research facilities within Israel, benefiting from the country’s established life sciences ecosystem.

Commercially, Evogene has a global market presence through partnerships and collaborations in North America, Europe, and Latin America, particularly within the agricultural sector. While the company does not operate large-scale manufacturing facilities, its technologies and products are designed for deployment across multiple continents through strategic partners and licensees.

Leadership & Governance

Evogene was founded by scientists associated with Compugen, reflecting its origins in computational genomics. The company is led by an executive team with expertise spanning biology, data science, and agribusiness, and is overseen by a board of directors responsible for governance and strategic oversight. Leadership emphasizes a platform-based innovation philosophy, focusing on long-term value creation through science-driven subsidiaries.

Key executives include:

• Ofer Haviv – President and Chief Executive Officer
• Chen Glick – Chief Financial Officer
• Dr. Elron Shani – Chief Technology Officer
• Dr. Gil Shapira – Chief Scientific Officer

The management team’s strategic vision centers on leveraging Evogene’s computational capabilities to address global challenges in food security, sustainability, and biological innovation, while maintaining disciplined capital allocation across its portfolio companies.